Who Prioritizes Innovation? R&D Spending Compared for Intra-Cellular Therapies, Inc. and Dr. Reddy's Laboratories Limited

Comparing R&D Priorities in Pharma Giants

__timestampDr. Reddy's Laboratories LimitedIntra-Cellular Therapies, Inc.
Wednesday, January 1, 20141240200000021226345
Thursday, January 1, 20151744900000087718074
Friday, January 1, 20161783400000093831530
Sunday, January 1, 20171955100000079419009
Monday, January 1, 201818265000000132166913
Tuesday, January 1, 20191560700000089124838
Wednesday, January 1, 20201541000000065782137
Friday, January 1, 20211654100000088845513
Saturday, January 1, 202217482000000134715000
Sunday, January 1, 202319381000000180142000
Monday, January 1, 202422873000000
Loading chart...

In pursuit of knowledge

Innovation in Pharmaceuticals: A Comparative Analysis

R&D Spending Trends

In the ever-evolving pharmaceutical industry, research and development (R&D) spending is a key indicator of a company's commitment to innovation. This analysis compares the R&D expenditures of Intra-Cellular Therapies, Inc. and Dr. Reddy's Laboratories Limited from 2014 to 2023.

Dr. Reddy's Laboratories consistently allocated a significant portion of its resources to R&D, with expenditures growing by approximately 84% over the decade. In contrast, Intra-Cellular Therapies, Inc. demonstrated a more modest increase, with R&D spending rising by around 750% during the same period, albeit from a much smaller base.

The data reveals a clear trend: while Dr. Reddy's Laboratories maintains a steady investment in innovation, Intra-Cellular Therapies, Inc. is rapidly scaling its efforts, reflecting its aggressive pursuit of new therapeutic solutions. Missing data for 2024 suggests ongoing developments in the industry.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025